MarketPeel
Insider Trading Intelligence
MM

Michael Lee Milligan

NMRA
SEE REMARKS · NEUMORA THERAPEUTICS, INC. · CIK 0001993953
FILING MIX · LIFETIME54%/46%
BUYS
13
SELLS
11
TOTAL VALUE
$8.5K
COMPANIES
1
ACTIVE SINCE
Feb 2024
HOLDINGS NOW
21,034
AVG SELL PX
$2.48
TRADE KIND
SHOWING 24 / 24
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizons · 4 pending
Forward-return performance of every backtestable P/S trade by Michael Lee Milligan, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+100.00%-3.58%-1.08%-2.50%-2.50%
14d2+100.00%-16.03%-3.02%-13.01%-13.01%
30d2+100.00%-30.18%-5.45%-24.73%-24.73%
60d2+100.00%-50.93%-4.83%-46.10%-46.10%
90d2+100.00%-53.26%+3.14%-56.40%-56.40%
180d2(1 pending)+100.00%-5.20%+5.52%-10.72%-10.72%
1y2(1 pending)+0.00%+107.51%+12.57%+94.94%+94.94%
2y2(2 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
NMRA · 21,034 shares · as of Feb 17, 2026
0100,000200,000300,000400,00020252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 13 buys / 11 sellsCOVERAGE · 9 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
NMRA
NEUMORA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,436$3.57$5.1K21,034Feb 17, 2026Feb 19, 2026View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
350,000350,000Jan 8, 2026Jan 9, 2026View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
400,000400,000May 28, 2025May 30, 2025View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
See Remarks
400,0000May 28, 2025May 30, 2025View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
See Remarks
28,6750May 28, 2025May 30, 2025View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
See Remarks
38,2340May 28, 2025May 30, 2025View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
28,67528,675May 28, 2025May 30, 2025View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
85,39185,391May 28, 2025May 30, 2025View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
See Remarks
41,2500May 28, 2025May 30, 2025View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
See Remarks
85,3910May 28, 2025May 30, 2025View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
41,25041,250May 28, 2025May 30, 2025View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
38,23438,234May 28, 2025May 30, 2025View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,978$1.69$3.4K22,470Feb 18, 2025Feb 20, 2025View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
See Remarks
41,2500Feb 13, 2025Feb 18, 2025View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
38,23438,234Feb 13, 2025Feb 18, 2025View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
See Remarks
38,2340Feb 13, 2025Feb 18, 2025View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
400,000400,000Feb 13, 2025Feb 18, 2025View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
See Remarks
85,3910Feb 13, 2025Feb 18, 2025View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
41,25041,250Feb 13, 2025Feb 18, 2025View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
85,39185,391Feb 13, 2025Feb 18, 2025View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
See Remarks
28,6750Feb 13, 2025Feb 18, 2025View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
28,67528,675Feb 13, 2025Feb 18, 2025View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
41,25041,250Feb 14, 2024Feb 16, 2024View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,62524,448Feb 14, 2024Feb 16, 2024View →
Other insiders · NMRA
Loading peer insiders…
About this filer
CIK 0001993953
ROLE
See Remarks
PRIMARY
NMRA
COMPANIES
1
ACTIVE SINCE
Feb 2024
MARKETPEEL · /INSIDER/0001993953DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback